Laboratory certification addresses the laboratory and its testing quality. Product authorization and evidence that a particular test use helps patients answer separate questions.
The U.S. Clinical Laboratory Improvement Amendments program sets laboratory-quality requirements for testing human specimens. CMS distinguishes analytical oversight under that program from clinical validity, which concerns what a result means for a clinical condition. A research-use label describes intended purpose; a laboratory-developed-test description concerns how and where a test is developed and used. FDA product authorization concerns a specified product and intended use. These descriptions can coexist and do not form one universal ladder of clinical usefulness or payment.
Shares Research use only (RUO), Analytical versus clinical validation.
Shares FDA laboratory-developed test (LDT) rule, Companion diagnostics.
Shares FDA laboratory-developed test (LDT) rule, Companion diagnostic, Companion diagnostics.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/